|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) have been developed to treat cancers including lung cancer.
|
30948928 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
|
30653748 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We then examined the effects of CAFs isolated from lung cancer tissues on programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma cell lines.
|
31462002 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also confirmed the up-regulation of PD-L1 by cisplatin, at both RNA and protein levels, in nude and immunocompetent mice bearing tumors grafted with A549, LNM-R, or LLC1 lung cancer cell lines.
|
31404614 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein levels of PD-L1 decreased in the primary culture of JQ1-treated renal carcinoma, prostate cancer, liver cancer, and lung cancer cell lines.
|
30958600 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our work shows the rationale for the treatment of lung cancer with a combination of PD-1/PD-L1 blockade and low-dose apatinib.
|
30755403 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunotherapy based on programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors may result in new treatment directions and a paradigm shift for Chinese patients with lung cancer.
|
30819828 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed the meta-analysis to evaluate the overall safety of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor treatment for lung cancer patients.
|
31348245 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Programmed death-ligand 1 (PD-L1) is a crucial target for lung cancer immunotherapy.
|
31741753 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combinatory administration of MEKi with either anti-PD-1 or anti-PD-L1 mAbs synergistically increased antitumor response and survival outcome compared with single-agent therapy in both the PKL-mediated syngeneic and transgenic lung cancer models.
|
30771521 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunotherapy targeting the programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) pathway has emerged as an effective treatment for lung cancer patients.
|
29683890 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this review is to: 1) analyze various preanalytical, analytical, and postanalytical factors influencing ICC results; 2) discuss measures for validation of ICC protocols; and 3) summarize published data on predictive ICC for ALK, ROS1, EGFR gene alterations and PD-L1 expression on lung cancer cytology.
|
31050216 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, LKB1 deficiency can promote an immunosuppressive microenvironment and may be involved in primary resistance to anti-PD-1/anti-PD-L1, as it has been reported in lung cancer.
|
30995715 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and programmed death ligand 2 (PD-L2) are immunomodulator molecules that have been the focus of research in lung cancer, melanoma, and renal cell cancer.
|
30134343 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A significant positive correlation between MET and PD-L1 expression in lung cancer was determined in an analysis based on The Cancer Genome Atlas (TCGA) and in an immunohistochemistry study.
|
31480591 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer.
|
31740722 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rarely, immunotherapy with anti-programmed cell death protein 1 and programmed death-ligand 1 antibodies across cancer may cause immune-related pulmonary toxicity, with a low overall incidence, being particularly low among patients with melanoma and highest among individuals with lung cancer.
|
30932979 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
|
31178388 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In combination with anti-PD-1 inhibitors, pegilodecakin increased the responses in RCC and lung cancer with efficacy agnostic to PD-L1 status and tumor mutational burden.
|
30790069 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erratum to the importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.
|
31019805 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that exosomes derived from lung cancer cells express PD-L1 and play a role in immune escape by reducing T-cell activity and promoting tumor growth.
|
31399559 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we assessed the tumor cell numbers and PD-L1 expression for Cryo with EBUS-GS for PPLs and TBB in patients with lung cancer.
|
31420048 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy.
|
31435660 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we evaluated the expression of PD-L1 on circulating tumor cells (CTCs) in patients with lung cancer.
|
31005568 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subsequent in vitro and in vivo experiments verified that the GNPs-hPD-L1 siRNA not only functioned as a carrier for siRNA delivery to down-regulate the hPD-L1 expression, but also served for photoacoustic (PA) imaging and photothermal agents for photothermal therapy (PTT) in both human lung cancer cells and human lung cancer cells-derived tumors.
|
31513911 |
2019 |